| Company Name: |
mahaloong
|
| Tel: |
+86-028-81192082 +86-18180560816 |
| Email: |
sales@mahaloong.com |
| Products Intro: |
Product Name:safusidenib
CAS:1898206-17-1
Purity:95% HPLC Package:1g；5g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Safusidenib
CAS:1898206-17-1
Package:100mg/RMB 17500;50mg/RMB 13800;25mg/RMB 10600
|
DS-1001b manufacturers
- Safusidenib
-
- $2500.00 / 100mg
-
2025-04-28
- CAS:1898206-17-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | DS-1001b Basic information |
| Product Name: | DS-1001b | | Synonyms: | Safusidenib;2-Propenoic acid, 3-[1-[[5-(1-fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1H-indol-4-yl]-, (2E)-;AB-218;DS-1001 | | CAS: | 1898206-17-1 | | MF: | C25H18Cl3FN2O4 | | MW: | 535.78 | | EINECS: | | | Product Categories: | | | Mol File: | 1898206-17-1.mol |  |
| | DS-1001b Chemical Properties |
| Boiling point | 651.9±55.0 °C(Predicted) | | density | 1.45±0.1 g/cm3(Predicted) | | pka | 4.37±0.40(Predicted) |
| | DS-1001b Usage And Synthesis |
| Uses | Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma[1]. Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively[2]. | | in vivo | Safusidenib (DS-1001b) has antineoplastic activity in JJ012 xenografts. Continuous administration of Safusidenib (mixed with sterilized pellet food and fed continuously for 6 weeks) impairs tumor growth in xenograft mice[1]. | Animal Model: | NOD-SCID bearing JJ012 xenograft[3] | | Dosage: | Mixed with sterilized pellet food (CRF-1; Oriental Yeast) and fed ad libitum for 6 weeks.
Mixed with sterilized pellet food (CRF-1; Oriental Yeast) and fed ad libitum for 6 weeks. | | Administration: | Fed continuously starting at 3 weeks | | Result: | Continuous administration significantly impaired tumor growth in JJ012 xenograft mice. |
| | IC 50 | IDH1 | | References | [1] Makoto Nakagawa, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019 Oct;38(42):6835-6849. DOI:10.1038/s41388-019-0929-9
[2] Yukino Machida, et al. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model. Mol Cancer Ther. 2020 Feb;19(2):375-383. DOI:10.1158/1535-7163.MCT-18-1349 |
| | DS-1001b Preparation Products And Raw materials |
|